Scientific article

Infections invasives à méningocoque de groupe B: un problème de santé publique non résolu

Published inRevue médicale suisse, vol. 7, no. 283, p. 447-450
Publication date2011

Group B meningococcal infections represent 64% of the invasive meningococcal infections in Switzerland. While conjugate vaccine against group C meningococcus is part of the additional vaccinations of the Swiss vaccinal calendar and quadrivalent vaccines protect against serogroups A, C, Y, and W135, there is presently no available vaccine against group B meningococcus in Switzerland. The use of the capsular polysaccharide from the group B meningococcus is ineffective and possibly dangerous because of its similarity with an adhesion molecule of the human neuronal cells. Development of new vaccines with other antigenic targets gives hope for an optimal protection not only against group B meningococcus, but also against other serogroups that share same antigenic determinants.

  • Humans
  • Meningitis, Meningococcal/immunology/prevention & control
  • Meningococcal Infections/epidemiology/immunology/microbiology/prevention & control
  • Meningococcal Vaccines/administration & dosage/adverse effects
  • Neisseria meningitidis, Serogroup B/isolation & purification/pathogenicity
  • Public Health
  • Switzerland/epidemiology
Citation (ISO format)
CRISINEL, Pierre-Alex, POSFAY BARBE, Klara. Infections invasives à méningocoque de groupe B: un problème de santé publique non résolu. In: Revue médicale suisse, 2011, vol. 7, n° 283, p. 447–450.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation12/13/2012 12:59:00 PM
First validation12/13/2012 12:59:00 PM
Update time03/14/2023 7:58:30 PM
Status update03/14/2023 7:58:29 PM
Last indexation01/16/2024 1:00:01 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack